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Introduction
Breast cancer is among the most common human cancers,
affecting one in every eight women and accounting for an
estimated 192,000 cases and more than 40,000 deaths
in the United States during 2001. One of the significant
predictors of breast cancer prognosis is regional and
distant metastasis; yet the mechanism of metastasis and
the ability to predict it are far from being fully understood.
From both a clinical and experimental perspective, a more
detailed understanding of the mechanisms of metastasis
is needed in order to identify better diagnostic markers
and therapeutic approaches.
In order to study breast cancer, many investigators have
used human derived cell lines that have yielded significant
insight into the biology of breast cancer; yet these models
DMEM = Dulbecco’s modified Eagle medium; EDTA = ethylenediamine tetraacetic acid; FBS = fetal bovine serum; H&E = hematoxylin and eosin;
MAPK = mitogen-activated protein kinase; mT = middle T; OPN = osteopontin; PBS = phosphate-buffered saline; PCR = polymerase chain reaction;
PI3-K = phosphatidylinositol-3-kinase; PyV = polyomavirus; SEM = scanning electron microscopy; SSH = suppression subtractive hybridization.
Available online http://breast-cancer-research.com/content/6/3/R157
Research article
Molecular analysis of metastasis in a polyomavirus middle T
mouse model: the role of osteopontin
Katayoun Alavi Jessen1, Stephenie Y Liu1, Clifford G Tepper2, Juliana Karrim1, Erik T McGoldrick3,
Andrea Rosner3, Robert J Munn3, Lawrence JT Young3, Alexander D Borowsky1,3, 
Robert D Cardiff1,3 and Jeffrey P Gregg1
1Department of Pathology, University of California, Davis, School of Medicine, Sacramento, California, USA
2University of California, Davis, Cancer Center, Sacramento, California, USA
3Center for Comparative Medicine, Schools of Medicine and Veterinary Medicine, University of California, Davis, California, USA
Corresponding author: Jeffrey P Gregg, jpgregg@ucdavis.edu
Received: 9 Oct 2003   Revisions requested: 25 Nov 2003   Revisions received: 28 Jan 2004   Accepted: 28 Jan 2004   Published: 25 Feb 2004
Breast Cancer Res 2004, 6:R157-R169 (DOI 10.1186/bcr768)
© 2004 Jessen et al., licensee BioMed Central Ltd. This is an Open Access article: verbatim copying and redistribution of this article are permitted
in all media for any purpose, provided this notice is preserved along with the article's original URL.
Abstract
Introduction: In order to study metastatic disease, we
employed the use of two related polyomavirus middle T transgenic
mouse tumor transplant models of mammary carcinoma
(termed Met and Db) that display significant differences in
metastatic potential.
Methods: Through suppression subtractive hybridization
coupled to the microarray, we found osteopontin (OPN) to be a
highly expressed gene in the tumors of the metastatic mouse
model, and a lowly expressed gene in the tumors of the lowly
metastatic mouse model. We further analyzed the role of OPN
in this model by examining sense and antisense constructs
using in vitro and in vivo methods.
Results: With in vivo metastasis assays, the antisense Met
cells showed no metastatic tumor formation to the lungs of
recipient mice, while wild-type Met cells, with higher levels of
OPN, showed significant amounts of metastasis. The Db cells
showed a significantly reduced metastasis rate in the in vivo
metastasis assay as compared with the Met cells. Db cells with
enforced overexpression of OPN showed elevated levels of
OPN but did not demonstrate an increase in the rate of
metastasis compared with the wild-type Db cells.
Conclusions: We conclude that OPN is an essential regulator of
the metastatic phenotype seen in polyomavirus middle T-induced
mammary tumors. Yet OPN expression alone is not sufficient to
cause metastasis. These data suggest a link between metastasis
and phosphatidylinositol-3-kinase-mediated transcriptional
upregulation of OPN, but additional phosphatidylinositol-3-
kinase-regulated genes may be essential in precipitating the
metastasis phenotype in the polyomavirus middle T model.
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remain an artificial in vitro system that may not reflect the
in vivo biology. Over the past decade, the laboratory
mouse has become the modern vehicle for human disease
studies [1], and genetically engineered mice are
particularly popular models for breast cancer (reviewed in
[2–4]). The mouse offers an in vivo experimental system
that can be manipulated and studied in great detail in
order to understand the complex biology of cancer.
To study metastatic disease, we have employed the use of
two related polyomavirus (PyV) middle T (mT) transgenic
mouse mammary carcinoma transplant lines (termed Met
and Db) that display significant differences in metastatic
potential [2,5–7]. The PyV-mT system is an ideal model to
study mammary carcinoma because there is rapid
mammary tumor formation with 100% penetrance, because
the histopathology of the PyV-mT tumors mimics that of
human breast carcinoma, and because, in many cases, the
human and mouse derived tumors are indistinguishable
[8,9]. The PyV-mT transgene has also been used as an
alternative, or a surrogate, for erbB2 in the mouse [10] as
the two molecules activate similar pathways. Desai and
colleagues [11] have recently shown that mammary
tumors derived from PyV-mT mice and from erbB2
transgenic mice show striking similarities at the
transciptome level.
Over the past few years c-erbB2 (HER2) has been shown
to be a key molecule in human breast cancer [12], being
overexpressed in 30–40% of human breast cancer cases
[13]. PyV is capable of transforming cells by triggering
signal transduction pathways that have been implicated as
activated by erbB2, through interactions between its mT
gene product and key cellular signaling proteins such as
c-Src [14,15], Shc, and phosphatidylinositol 3-kinase
(PI3-K) [16], which have all been implicated as important
in human breast cancer. Specifically, with respect to
PI3-K, mT interacts with the 85 kDa regulatory subunit of
PI3-K to activate PI3-K [17], which has been implicated as
a key signal in carcinoma invasion [18].
The Met model, derived from transgenic mice constructed
with the wild-type PyV-mT line, develops rapid mammary
carcinoma in all animals with 100% pulmonary metastasis
[5]. In contrast, the Db model derived from animals with
double site-directed mutations at amino acid residues 315
and 322 of the PyV-mT is decoupled from the PI3-K
pathway. The Db model has 100% penetrance of
mammary tumor but exhibits significantly fewer pulmonary
metastases (9%) [7,16,19]. Similar metastatic rates were
observed when Met and Db tumor lines were transplanted
into syngeneic FVB mice [20]. The site-directed mutations
at residues 315 and 322 interfere with the recruitment of
the p85 subunit of PI3-K [16], and thereby PI3-K is not
recruited and activated. This subtle difference in the mT
gene significantly affects the metastatic phenotype.
Because disruption of the PI3-K pathway in this model
suppresses metastasis, and because of the purported role
of PI3-K in carcinoma cell invasion, we wanted to identify
the key regulators that are differentially expressed
between the Met tumors and the Db tumors, as well as to
validate their role in metastasis. We utilized suppression
subtractive hybridization (SSH) coupled to the microarray
in order to initially identify targets [21,22]. SSH is a
technique that generates cDNA libraries of transcripts that
are differentially expressed between two populations of
cells, normalizing for variable mRNA abundance by
enrichment of rare transcripts [23].
Using SSH in conjunction with microarrays, we identified
osteopontin (OPN) as a very highly expressed gene that
was expressed more than threefold higher in the Met
tumor lines compared with the Db tumor lines. Immuno-
histochemical analysis of the tumors confirmed the
presence of OPN with a marked cytoplasmic stain in the
Met tumor cells and an absence of staining in the Db
tumor cells. Cell lines were developed from these tumors,
and they showed differential expression of OPN in similar
proportions. Furthermore, OPN expression directly
correlated with the ability of the tumor-derived cell lines to
migrate in response to serum. Correspondingly, antisense-
mediated attenuation of OPN expression reduced the
migratory capacity of Met cells (in a cell line termed Met-
As), while enforced OPN expression in Db cells stimulated
migration (in a cell line termed Db-S). In in vivo metastasis
experiments, the wild-type Met cells showed a high rate of
metastasis to the lungs of recipient mice, whereas the
Met-As cells did not metastasize to the lungs of recipient
mice. In contrast, the Db cells manifested a metastasis
rate that was significantly lower than that of wild-type Met
cells. However, the Db-S cells, with elevated OPN levels,
showed no increase in the metastasis rate when
compared with the wild-type Db cells.
Scanning electron microscopy (SEM) of the OPN
antisense transfected Met line shows morphologic change
consistent with a less metastatic phenotype, while the
OPN-transfected Db cells show morphologic change
consistent with a more metastatic phenotype. Given this
evidence, we conclude that PyV-mT induces a metastatic
phenotype, at least in part, through the PI3-K-mediated
transcriptional upregulation of the matrix protein OPN,
although enforced expression of OPN in the lowly
metastatic Db cells does not increase their metastasis
rate. We therefore conclude that OPN is essential for
metastasis in the PyV-mT system, but that elevated OPN
expression alone is not sufficient to induce metastasis.
Methods
Mammary tumor transplants and cell lines
Three-week-old nontransgenic FVB female mice were
anesthetized with a 1:12 xylazine/1: 24 ketamine cocktail
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in PBS, administered at 0.012 ml/g intraperitoneally. The
abdominal (#4) mammary glands were cleared of growing
epithelium as previously described [24,25]. Tissue
segments (1 mm3) of Met tumors and of Db tumors were
transplanted into the cleared mammary fat pads. The
animals were killed 28–35 days later by a double dose of
anesthesia, and tumor tissue was harvested from the
mammary fat pads of recipient nontransgenic FVB female
mice. Mammary tumor cell lines were developed from the
Met tumors and the Db tumors with a collagenase
digestion technique coupled with differential centrifuga-
tion, as previously described [19,26,27]. The cells lines
were then maintained and grown in 100 mm tissue culture
dishes using DMEM (pH 7.4) supplemented with 10%
heat-inactivated fetal bovine serum (FBS), and
1 × antibiotic/antimycotic (Invitrogen Corp., Carlsbad, CA,
USA) [24,25].
cDNA subtracted libraries and arrays
RNA was isolated from the tumors by homogenizing with a
Polytron generator (Brinkmann Instruments, Westbury,
NY, USA), using the acid guanidinium thiocyanate–phenol–
chloroform extraction method [28]. Subtracted Met
libraries and Db libraries were generated using the PCR-
Select cDNA Subtraction Kit, as recommended by the
manufacturer (BD Biosciences Clontech, Palo Alto, CA,
USA). This yielded two libraries: one containing genes
expressed in Met but not in Db, and one containing genes
expressed in Db but not in Met. Both subtracted libraries
were subsequently subcloned into the TA-cloning vector
(Invitrogen Corp.), picked and cultured in 96-well plates,
PCR-amplified, and arrayed onto silanized slides as
described previously [29].
Each SSH library was then fluorescently labeled with either
Cy3-conjugated or Cy5-conjugated dCTP and hybridized
to the arrays to screen for true differential expression. The
slides were scanned on an Affymetrix 418 two-color
fluorescent scanner (Affymetrix Inc., Santa Clara, CA,
USA), each creating a 16-bit TIFF image. The images
were downloaded from the scanner and analyzed using a
commercial software program (ImaGene; BioDiscovery
Inc., Marina Del Rey, CA, USA), which automatically
detects the regions of fluorescent signal, determines the
signal intensity, performs global normalization, and
compiles the data into a Microsoft Excel spreadsheet for
further analysis. The program determines the Cy3/Cy5
expression ratios for each data point. All ratios are log-
transformed (log base 2 for simplicity).
The subcloned arrayed products were then categorized
and ranked with respect to differential expression and
signal intensity. Products that showed both differential
expression and high signal intensity were sequenced for
identity. The products were sequenced by Davis
Sequencing (Davis, CA, USA).
RNA analysis and northern blots
Met and Db cells were plated at 1 × 106 cells/100 mm
plate and were allowed to attach overnight. Total RNA
was extracted using the TRIzol reagent (Invitrogen Corp.).
Met tumors and Db tumors were harvested and the total
RNA was isolated by homogenizing with a Dounce
homogenizer (Kimble Kontes, Vineland, NJ, USA), using
the acid guanidinium thiocyanate–phenol–chloroform
extraction method [28].
For northern blot analysis, total RNA was quantitated,
denatured, and electrophoresed in an agarose-
formaldehyde gel, with subsequent transfer to a Hybond N
nylon filter by standard methods (Amersham Biosciences
Corp., Piscataway, NJ, USA). Procedures for pre-
hybridization, hybridization, filter washing, and filter stripping
were performed as described previously [30]. Filters were
hybridized with 32P-labeled cDNA probes of mouse OPN
(AF808; R&D Systems, Minneapolis, MN, USA) and 18s
ribosomal RNA (as a control). The blots were scanned
using a phosphorimager and normalized to 18s rRNA levels
to determine the relative changes in OPN mRNA.
Histology and immunohistochemistry
Tumors were fixed overnight in formalin, were paraffin-
embedded, and were sectioned at a thickness of 5 µm.
Normal FVB kidney and lactating mammary glands were
similarly processed as normal control tissue for OPN.
Routine H&E staining was performed. Microwaving in a
citrate buffer was used for antigen retrieval. For the OPN
immunohistochemistry studies, anti-OPN (AF808; R&D
Systems) was used at a dilution of 1: 800 and was
detected using the Vector ABC kit (Vector Laboratories,
Burlingame, CA, USA). The images were captured using a
Kontron Model 3012 CCD camera on an Olympus BH2
microscope. They were digitized using Photoshop 6.0
with the Kontron ProgRes ‘plug-in’ module, were color
enhanced, were balanced for contrast and were printed
using a Kodak 8650 dye sublimation printer.
Production and characterization of stably transfected
cell lines
To generate the constructs used for the production of
stable cell lines, the full-length murine OPN cDNA was
obtained by reverse-transcription PCR from Met cells
using the 5′ primer GGA ATT CCT TGC TTG GGT TTG
CAG TCT TCT G and the 3′ primer GCT CTA GAA CAT
TCG TTA CAA GAT TTA TTC AC. These primers were
designed to amplify the entire coding sequence, excluding
the 3′ termination codon and including restriction sites
EcoRI and XbaI (underlined). The products were ligated in
either the sense or the antisense orientation into the EcoRI
and XbaI sites of the eukaryotic expression vector
pCDNA3.1(+/–). The constructs were then transfected
into Db and Met cell lines using standard calcium
phosphate transfection methods, after which the cells
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were treated with G418 sulfate (Geneticin; Invitrogen
Corp.) to select for the integration of the construct into the
genome [31].
Control cell lines were generated by transfecting Met cells
and Db cells with the empty pCDNA3.1(+/–) vector. The
stably integrated lines were identified by northern blot
analysis using the neomycin and OPN gene-specific
probes [32]. The stable cell lines were then propagated in
selective media that contained 600 µg/ml G418 sulfate.
The cells were incubated in a humidified atmosphere of
95% air and 5% CO2 at 37°C. For subculturing, cells
were trypsinized (0.05% trypsin and ethylenediamine
tetraacetic acid [EDTA]) and were plated at 1 × 106 cells/
100 mm plate.
Migration assays
For the migration assay, 24-well transwell units with
0.8 µm porosity polycarbonate filters were used (Corning,
Inc., Big Flats, NY, USA). Cells were harvested by
trypsinization and were counted. Then 5 × 103 cells were
resuspended in 100 µl serum-free medium and placed in
the upper chamber of the transwell unit. The bottom
chamber contained 500 µl medium with serum as a chemo-
attractant [33]. The transwell units were then placed in a
37°C humidified 95% air/5% CO2 atmosphere for
18–24 hours. Cells on the upper surface were then
removed by wiping with a cotton swab, while the remaining
cells were fixed with 10% formalin and stained with
hematoxylin. Visualization of the membrane and cells was
performed with a phase contrast microscope. Migration was
quantitated by determining the number of cells (averaged
among four representative fields using a 20 × objective) that
had migrated to the lower side of the filter.
In vivo tail vein metastasis analysis
The tail vein inoculation assay, which tests the ability of
the cells to survive in the blood stream, to colonize, and to
grow in the lung [34], was used to test the metastatic
potential of the cells. Met cells, Met-As cells, Db cells, and
Db-S cells were grown under selection (using 600 µg/ml
G418 sulfate) in DMEM (pH 7.4) supplemented with 10%
heat-inactivated FBS and 1 × antibiotic/antimycotic. The
cells were incubated at 37°C in a humidified atmosphere
containing 95% air and 5% CO2. Cells were harvested at
80–90% confluence by trypsinization (0.05% trypsin–
EDTA), washed, and resuspended in 1 × PBS (pH 7.4).
For injection with each cell line, eight nude mice (Nu/Nu;
Jackson Laboratories, Bar Habor, ME, USA) were used
(four mice at each of two concentrations: 1 × 104 cells
and 1 × 106 cells). The animals were anesthetized with
0.6% sodium pentobarbital at a dosage of 10 µl/g body
weight, and cells in a total volume of 50 µl were injected
into the tail vein of each mouse. Mice were monitored for a
total of 6 weeks and were then sacrificed. The lungs of
each mouse were analyzed by whole mount hematoxylin
staining for metastatic foci.
For whole mount lung preparation, each mouse was
sacrificed by anesthetic overdose. The lungs were perfused
with 4% buffered formalin via cannulation of the trachea and
were forcibly inflated to ensure adequate distribution of
fixative. The lungs were removed and the lobes separated
and placed into a Tissue-Tek uni-cassette (Sakura Finetek
USA, Torrance, CA, USA) for fixation and whole mount
processing. After fixation, the lungs were dehydrated with
alcohol (70%, 95%, and absolute alcohol for 1 hour each
step), cleared with xylene, and then hydrated for Mayer’s
hematoxylin staining. After 3 min of staining, the excess stain
was removed with a 1% hydrochloric acid solution. The
lungs were again dehydrated with alcohol, cleared in xylene,
and then placed in methyl salicylate for microscopic analysis
and photography.
In vivo mammary fat pad metastasis analysis
Met cells, Db cells, Met-As cells, and Db-S cells were
assayed for metastatic potential by injection into the
mammary fat pad of FVB mice. Each cell line was grown
under G418 sulfate (600 µg/ml) selection in DMEM
(pH 7.4) supplemented with 10% heat-inactivated FBS
and 1 × antibiotic/antimycotic. These lines were grown at
37°C in a humidified atmosphere containing 95% air and
5% CO2, and cells were then harvested at 80–90%
confluence. For the harvest, cells were trypsinized (0.05%
trypsin–EDTA), washed with 1 × PBS (pH 7.4), and resus-
pended to a concentration of 1 × 105 cells/µl in Matrigel
(BD Biosciences, Franklin Lakes, NJ, USA).
Ten FVB mice were used for each cell line. The mice were
anesthetized and surgery was performed to expose the left
#4 fat pad of each mouse. Twenty microliters of the
cell–Matrigel suspension were injected into each exposed
fat pad, and the mice were allowed to recover. The
animals were monitored for tumor growth, and tumors
were removed from the animals when they reached 1.5 cm
in diameter (22–26 days postinjection). The mice were
again allowed to recover and were monitored for the
development of lung metastases. This tumor removal
survival surgery is necessary because these tumors
become very large at 3 weeks (approximately 1.5 cm),
which significantly affects the health of the animals. The
mice were sacrificed and lungs from the animals were
harvested at 42 days postinjection. Whole mount analysis
was performed on the lungs in order to identify and
enumerate metastases.
Protein extraction and western blot analysis
To assess OPN protein levels, the cells/tumors were
placed in a hypotonic solution (10 mM Tris) and homo-
genized using a Dounce homogenizer. The cell lysate was
centrifuged at 15,000 × g for 10 min, and the supernatant
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was designated as the crude cytoplasmic fraction [31].
The intracellular protein concentration was then quanti-
tated using the BCA assay (Pierce Chemical Company,
Rockford, IL, USA). Protein preparations were subjected
to SDS-PAGE on 12% gels, were transferred onto a
polyvinylidenedifluoride membrane, and were incubated in
a blocking solution (5% w/v Blotto). This was followed by
an overnight incubation with goat antimouse OPN
antibody. After being washed, membranes were incubated
with horseradish peroxidase-conjugated rabbit antigoat
IgG for 1 hour [31]. The enzyme bound to OPN was
visualized using an enhanced chemiluminescence
detection kit (ECL; AP Biotech, Piscataway, NJ, USA). The
blot was then stripped and incubated with antimouse
β-actin antibody as a control (Santa Cruz Biotechnology,
Santa Cruz, CA, USA). The blots were scanned using a
phosphorimager and normalized to the β-actin levels to
determine the relative changes in levels of OPN protein.
Scanning electron microscopy
Whole filter assemblies (0.8 µm porosity; Corning, Inc.)
were fixed in modified Karnovsky’s fixative consisting of
2% paraformaldehyde and 2.5% glutaraldehyde in
0.06 M Sorenson’s phosphate buffer (pH 7.2–7.4).
Fixation continued for 4 hours to overnight at 4°C. The
filter assemblies were then rinsed three times for 2 min
each in 0.1 M phosphate buffer at 4°C. Dehydration was
started in 30% ethanol and then in 50% ethanol for 5 min
each at 4°C. Dehydration continued in 70%, 95%, and
100% ethanol for 5 min each at room temperature. The
filter assemblies were then critical point dried utilizing
liquid carbon dioxide.
After drying, the filter disks were carefully cut from the
filter assemblies and mounted onto SEM specimen
supports using multiple thin strips of double-sided Scotch
tape. One-half of each filter disk was mounted with the
‘top’ facing upward, and the other half was mounted with
the ‘bottom’ facing upward. The samples were then
coated with gold in a sputter coater (Ted Pella, Inc.,
Redding, CA, USA). The samples were examined and
photographed using a Philips XL30TMP scanning electron
microscope (FEICO/Philips, Hillsboro, OR, USA). Images
were recorded onto 4’×5’ Polaroid 55P/N film as well as
using direct digital imaging.
Results
We expected this model to provide a well-controlled
system in which to identify metastasis-related genes
because the Met tumors and Db tumors were propagated
in the same mouse strain (FVB). The only difference
between the transgenes is the presence of the two point
mutations in the middle T gene in the Db mice. Our
ultimate goal was to identify a key regulator that is
differentially expressed in the Met tumors and in the Db
tumors.
Identification of OPN using SSH and microarray analysis
Following SSH and array analysis (Fig. 1 shows a section
of the SSH array), clones that displayed differential
expression and high signal intensity were sequenced. We
sequenced clones in batches of 10. OPN was identified
three times in the first sequencing pass. The identification
of a single gene three times in this initial sequencing batch
was unexpected because the normalization step in the
SSH procedure is designed to give equal value to both
highly expressed and lowly expressed genes. In sub-
sequent experiments, we have found that this procedure
does tend to lead to clone redundancy in highly expressed
genes that are differentially expressed. The OPN clones
had the highest intensity signals on the array. We
confirmed this in subsequent experiments using Affymetrix
U74Av2 GeneChip arrays, where OPN is seen to be
overexpressed in the Met tumor compared with in the Db
tumors (data not shown). Since OPN displayed significant
differential expression and a high level of intensity, we
decided to analyze this gene in more detail before
continuing the sequencing of the SSH libraries.
OPN transcript expression in Met and Db cell lines and
tumors
Northern blot analysis was used to validate the array
results in the Met tumors and the Db tumors. With respect
to OPN expression, transcript levels were fourfold higher
in the Met tumor versus the Db tumor. In order to study
OPN at the cellular level, Met and Db cell lines were
established. Northern blot analysis was also used to
determine that OPN was differentially expressed in vitro in
these cell lines. These analyses showed that OPN
expression was 3.5-fold higher in the Met cell line versus
the Db cell line. Figure 2 shows a northern blot of both the
tumors and cell lines, demonstrating that the tumors and
cell lines show similar differential expression of OPN.
Immunohistochemical staining for OPN in Met tumors
and Db tumors
Ten Met tumors and 10 Db tumors from different transplant
generations were histologically and immunohistochemically
analyzed. H&E staining of the tumor sections showed that
the Met tumors formed more glands and had lower mitotic
indices and smaller nuclei than the Db tumors.
Immunohistochemistry staining with OPN antibody
confirmed that OPN was differentially expressed at the
protein level and originated from the tumor cells (Fig. 3).
As a group, Met tumors showed diffuse cytoplasmic OPN
staining with more intense staining in the peripheral areas
of the tumor. The OPN staining was weak or absent in the
lumina of the tumor glands. The Db tumors, as a group,
showed OPN staining in less than 1% of the tumor cells,
usually located either close to the stroma or close to
necroses. In both groups, extracellular OPN was present
in necrotic tumor areas.
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For comparison, we performed immunohistochemical
staining of two mammary glands from normal lactating
FVB mice. This showed that OPN was localized in the
lumen and at the luminal membrane of alveolar cells and
ductal cells (data not shown). Because of its differential
expression at both the RNA level and the protein level,
OPN was chosen to test the hypothesis that this gene,
identified by array analysis, plays a significant role with
regard to cell migration/metastasis in the PyV-mT model.
Met cells have a higher migratory potential than Db cells
Because of the known role of OPN in increased cell
migration [35], we tested the idea that Met cells are more
capable of migration than are Db cells. Migration assays
were used to determine the migratory potential of these
cells. Figure 4a shows a typical 40 × magnification field of
the transwell unit membrane after removal of the
Breast Cancer Research    Vol 6 No 3 Jessen et al.
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Figure 1
Representative region of the suppression subtractive hybridization
(SSH) microarray of the Met and Db tumor lines. (a) The SSH libraries
were arrayed, probed with fluorescence-labeled aliquots of each
library, and scanned with a two-color fluorescent scanner. Green
represents higher expression in the Met line, and red represents higher
expression in the Db line. (b) Analysis of the same section of the SSH
array with the GenePie function of ImaGene (BioDiscovery, Inc.,
Marina Del Rey, CA, USA) shows the relative percentage of signal
intensity at each spot of the two fluorescent labels. Probes were
selected for sequencing on the basis of high expression and
differential expression. Osteopontin (OPN) was identified as being
highly differentially represented in the Met subtraction library and is
marked with arrows on the array in (a) and (b).
Figure 2
Northern blot of cell lines and tumors from Db and Met. RNA was
isolated from Met and Db tumors and from Met and Db cell lines, and
probed on a northern blot using 32P-labeled mouse osteopontin (OPN)
cDNA. The 18s ribosomal RNA was used as a control. The 1.6 kb
OPN transcript level is fourfold higher in the Met tumor than in the Db
tumor, and is 3.5-fold higher in the Met cell line than in the Db cell line.
Figure 3
Immunohistochemical analysis of osteopontin (OPN) in the Met and Db
tumor tissues. Sections from 10 Met tumors and from 10 Db tumors
were stained using immunohistochemistry with antimouse OPN
antibody. Representative sections are shown. (a) The Met tumor
shows diffuse cytoplasmic OPN staining in the tumor cells, particularly
in the periphery of the tumor. (b) The Db tumor cells generally did not
stain for OPN.
nonmigratory cells. Met cells demonstrated a migratory
capacity approximately 19 times that of Db cells
(P = 0.001; Fig. 4c) in response to serum.
Inhibition of the OPN gene results in the reduction of
migration
Given this cell line model that showed differential
expression of OPN and differential migration potential, we
tested the hypothesis that OPN is essential to the
establishment and maintenance of the metastatic
phenotype in our model. In order to test this hypothesis,
we generated Met sublines and Db sublines having
suppressed or enforced expression of OPN, respectively.
These were generated by stable transfection of the
indicated cell lines with expression constructs containing
the full-length OPN cDNA in either the sense or the
antisense orientation, and were referred to as Met-As and
Db-S, respectively. Vector-only controls were also
generated for each cell line. Immunoblot analysis of
detergent lysates demonstrated that OPN antisense
expression in Met markedly reduced basal OPN
expression to barely detectable levels, similar to that
observed in the Db vector control (Fig. 5a). Conversely,
OPN expression was successfully elevated in Db-S.
Relative OPN expression was determined by
densitometry, indicating that OPN was reduced eightfold
and was increased 3.5-fold in Met-As and in Db-S,
respectively, compared with their vector control
counterparts (Fig. 5b,c).
Migration assays were performed to determine the native
migration potential of all the lines (Fig. 5d). Five unique
clones from each line were tested for their migration
capability. As a group, the Met-As clones showed
decreased migration, while the Db-S clones showed an
increase in its migration capacity. A representative clone
from each line was used for more definitive analysis. Met-
As showed a threefold decrease in the number of cells
that migrated, as compared with the Met control
(P < 0.001). Db-S cells showed a more than 10-fold
increase in the number of migratory cells as compared
with the Db control (P = 0.001).
Overall, we observed a direct relationship between OPN
protein expression and cell migration. The overexpression
of OPN correlates with an increased migration potential of
cells, and the inhibition of OPN correlates with a decrease
in migration.
In vivo tail vein metastasis assays
To assess the importance of OPN with respect to
metastasis in the mouse, we performed in vivo tail vein
injections of wild-type Met cells, Met-As cells, Db cells,
and Db-S cells into nude mice. In both the low
concentration (1 × 104) sets and the high concentration
(1 × 106) sets of cell injections, the Met cells showed
tumor metastasis to the lung while the Met-As cells
showed no tumor metastasis. The Db control cells are
known to embolically colonize the lungs in tail vein
injection experiments, and subsequent analysis of the Db
cells and Db-S cells showed metastasis rates and tumor
volumes similar to those of Met cells, despite low
metastatic frequency in orthograft transplantations [20].
In summary, 100% of the animals in the Met group, the Db
group, and the Db-S group showed metastasis. This
metastasis analysis was assessed by gross, whole mount,
and histologic analysis. Figure 6a,b shows images of the
whole mounts of lungs from a representative Met wild-type
animal and from a representative Met-As animal. Figure 6c
is a photograph of the lung cavity of a mouse injected with
1 × 106 Met cells. In all of the animals injected with
1 × 106 Met cells, the lungs were nearly filled with tumor
and it was impossible to count individual foci. In these
cases, we estimated the amount of lung volume occupied
by the tumor.
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Figure 4
Migration of Db cell lines and Met cell lines in response to serum. Cells
were placed in serum-free medium in the upper chamber of transwell
units with 8 µm porosity polycarbonate filter membranes. Medium with
10% FBS was used as a chemoattractant in the lower chamber. Cells
were incubated for 18–24 hours, and the cells on the upper surface
were removed and the cells on the lower surface were fixed and
stained. Cells were visualized with a phase contrast microscope and
were photographed. (a) A representative field (40 × magnification)
showing very few Db cells migrated in response to the serum. (b) A
representative field (40 × magnification) of Met cells showing a much
higher number of migratory cells. (c) Migration was quantitated by
assessing the mean number of cells that had migrated through the
membrane in four representative 20 × fields. Met cells demonstrated a
migratory capacity 19 times higher than Db cells (P = 0.001).
In vivo fat pad metastasis analysis
Because the tail vein experiments do not recapitulate all
the necessary steps that a cell needs to perform in order
to metastasize from an ectopic site, we performed
mammary fat pad injections with Met cells, Db cells, Met-
As cells, and Db-S cells in order to mimic the entire
metastasis cascade.
All the groups had approximately the same growth rate in
terms of tumor size (data not shown), and tumors were
removed at days 22–26 from each animal. The animals
were then followed for an additional 21 days and sacri-
ficed at day 42 in order to examine the lungs. Three mice
injected with Met cells expired at tumor harvest due to
significant blood loss from the large vascular tumors. One
mouse in the Db group expired after the surgery due to
unknown causes. These four mice were necropsied and
no metastasis was found. These were not included in the
final analysis.
Results from whole mount analysis of the lungs are
depicted in Fig. 6d. The Met group had the highest rate of
metastasis, the Db group and the Db-S group had a low
metastasis rate, while the Met-As group had no
metastasis. In the Met group, the number of metastatic
foci per animal ranged from one to eight, except for one
animal that expired 18 days after the survival surgery,
whose lungs were completely filled with tumor. The
animals in the Db group and the Db-S group with
metastasis each had a single focus of metastatic tumor.
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Figure 5
Analysis of osteopontin (OPN) expression and cell migration in Met-As and Db-S stable cell lines. (a) Detergent lysates were prepared from the
indicated cell lines. Proteins were size-fractionated by 7.5% SDS-PAGE and transferred to a polyvinylidenedifluoride membrane and analyzed for
OPN expression with antimouse antibody (AF808; R&D Systems, Minneapolis, MN, USA). OPN migrated as a doublet, presumably due to isoforms
generated by different levels of glycosylation (arrows). Molecular mass standards are indicated on the left-hand side. The lowermost band present
in all four lanes is due to nonspecific binding. (b) Relative OPN expression and (c) the fold change in OPN expression in Met-As cells and Db-S
cells compared with their relevant vector-transfected control cell lines were determined in the blot in (a) using the TotalLab version 2.00 software
package (NonLinear Dynamics, Ltd, Durham, NC, USA). (d) Migration assays were performed on the Db-S cells, Met-As cells, Db control cells, and
Met control cells. Met-As cells showed a threefold decrease (P < 0.001) in the number of cells that migrated in comparison with the Met control
cells. Db-S cells showed a 10-fold increase (P = 0.001) in migration when compared with the Db control cells.
Sense and antisense constructs alter the morphology of
the cells
Finally, we wanted to test the hypothesis that the change
in migratory potential in these cells is due to the effect of
OPN on the cytological architecture of the cell. Using
SEM, we examined the morphology of the various cell
lines (Fig. 7). The surface membrane of the Met cells was
extremely rough with numerous and highly branched
filopodia, whereas the Db cells were much smoother and
lacked branched filopodia. In contrast, the Met-As cells
had a smoother cell surface with fewer branched filopodia
when compared with the Met wild-type cells, resembling
the Db wild-type cells. The Db-S cells had a rougher
exterior and had a minor increase in the number of
branching filopodia compared with the Db wild-type cells.
Discussion
The goal of this study was to identify and functionally
validate key molecules that may be responsible for the
metastatic phenotype seen in the PyV-mT transgenic
model. We show that OPN is transcriptionally over-
expressed in the metastatic line with mT/PI3-K interaction,
compared with the lowly metastatic line without mT/PI3-K
interaction. We further demonstrate the differential
expression of the OPN protein by western blot and
immunohistochemistry. In vitro and in vivo studies
demonstrate that OPN is required for the metastatic
phenotype in the PyV-mT. This is demonstrated by the
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Figure 6
In vivo metastasis analysis via tail vein injection assays and mammary fat pad injection assays. Using the tail vein, nude mice were inoculated with
Met wild-type cells and Met-As cells. The lungs of these mice were dissected at 6 weeks and were subjected to whole mount hemotoxylin staining.
(a) Lungs of mice injected with 1 × 106 Met wild-type cells were nearly completely infiltrated with metastatic foci (dark regions). (b) Lungs of mice
injected with 1 × 106 Met-As cells were free of metastatic foci. (c) Lung cavities of mice injected with 1 × 106 Met wild-type cells were filled with
grossly visible metastatic foci. (d) Met cells and Met-As cells were injected in the mammary fat pad of FVB mice. Whole mount analysis of the lungs
was performed 42 days after injection. One hundred percent of the Met animals had metastasis (n = 6), while metastasis was not seen in any of
the Met-As animals (n = 10). In contrast, in the Db group, two out of nine animals (22%) had metastasis, and the Db-S group had a similar rate of
metastasis (two out of 10 animals [20%]).
Figure 7
Alterations in cell morphology by induction and inhibition of osteopontin
(OPN). Scanning electron microscopy was used to visualize differences
in cell morphology between the transfected cell lines. (a) Micrograph of
control Met cells, (b) micrograph of control Db cells, (c) micrograph of
Met-As cells, and (d) micrograph of Db-S cells. These images indicate
a correlation between lower OPN expression and a decrease in
branched filopodia and roughness of the cell membrane.
Met-As cells, in which OPN expression is nearly
completely abolished. The suppression of OPN was seen
to eliminate the ability of the PyV-mT cells to migrate in
vitro, to colonize the lungs in tail vein injections, and to
metastasize to the lungs in the mammary fat pad assay. In
contrast, the studies in the Db cells demonstrate that
overexpression of OPN alone is not sufficient to effect a
metastatic phenotype, as evidenced by the lack of
correlation between increased OPN levels and the
metastasis rate in the Db-S cells. This suggests that other
PI3-K-mediated genes are important and may cooperate
with OPN in producing the metastasis phenotype in the
PyV-mT system.
OPN has been shown to be important in the developing
mammary gland and in cancer. It is a necessary
component for mammary gland development and lactation,
and is particularly important in the differentiation of the
terminal alveolar structure [36–38]. With regard to its role
in cancer, previous studies have shown OPN to be a
secreted, integrin-binding glycophosphoprotein whose
plasma concentrations are elevated in metastatic breast
cancer and are associated with increased tumor burden
and decreased survival [39]. In addition, it has been
shown, by immunohistochemistry and in situ hybridization,
that OPN expression is associated with decreased
disease survival and decreased overall survival in node-
negative breast cancer [40].
Rudland and colleagues [41] recently showed that OPN is
tightly linked with decreased survival in stage I and stage II
breast cancer. Urquidi and colleagues [42] have demon-
strated overexpression of OPN in sublines of the MDA-
MB-435 breast tumor cell line that were selected for a
high metastatic potential as compared with the non-
metastatic sublines. Studies in humans and human derived
cell lines demonstrate that OPN is associated with both
breast carcinoma and with metastatic breast carcinoma,
and confirm that the breast cancer cells are a significant
source of OPN expression [43]. In nonhuman studies,
Oates and colleagues [44] have shown that increasing the
expression of OPN is sufficient to produce a metastatic
phenotype in a previously benign cell line (rat mammary
tumor line). Behrend and colleagues [45] have shown in
nonmammary systems that attenuation of OPN with anti-
sense methods can reduce metastasis in ras-transformed
NIH 3T3 cells. Gardner and colleagues [46] have shown
the same effect in transformed Rat1 fibroblasts.
These studies, in humans and in animal models,
demonstrate an association of OPN with breast/mammary
carcinoma, and specifically with metastatic disease. To
observe a more direct association of OPN and metastatic
potential, we used our model system, with its metastatic
line and a nonmetastatic line, to manipulate OPN
expression by overexpressing it in the nonmetastatic line
and by abrogating its expression in the metastatic line, and
observing whether the presence or absence of OPN can
affect the phenotype with regard to metastasis. Cell
migration was used for this initial analysis, as it is one of the
hallmarks of invasive behavior [47]. In the Met lines, using
antisense methodology, we were able to significantly
decrease the OPN protein expression to nearly un-
detectable levels. This decrease in OPN protein expression
was associated with a threefold decrease in the number of
cells that migrated, as compared with the vector-transfected
Met control. In in vivo tail vein and mammary fat pad
injection experiments, this decrease in OPN expression was
associated with an elimination of metastatic ability. We
viewed these results as indicating that OPN is essential for
the metastasis phenotype in the Met lines.
In turn, with the overexpression of the OPN protein in the Db-
S cells (3.5-fold higher than the control Db cells and 6.5-fold
higher than the Met-As cells), there was a significant
increase in the migratory potential of these cells. Specifically,
the migration of the Db-S cells was increased at least 10-
fold over the vector-transfected wild-type Db cells, twofold
over the Met-As cells, and was shown to be about one-half
the rate of the Met wild-type cells. We therefore postulated
that this level of OPN overexpression would have further
consequences in the in vivo experiments.
The observation that there was no increase in the
metastasis rate in the fat pad experiments in the Db-S line,
despite increased OPN expression and the increased
migration of the cells in vitro, was surprising. The Db-S
cells had a similar rate of growth assessed by tumor size
when compared with the wild-type lines and Met-As. In
addition, the primary tumors remained positive for the
expression of OPN, as demonstrated by immuno-
histochemical analysis. These observations suggest that in
the Db system OPN may play a role in the migration
capacity of the cells, but other genes are necessary to
recapitulate the entire metastatic cascade. Because the Db
system is deficient in terms of the activation of PI3-K, these
cooperative genes are most probably PI3-K dependent.
The tail vein metastasis assays were uninformative in the
Db system. As such, they are illustrative of the limitations
of this assay. The wild-type Db cells colonize the lung with
the same frequency as the wild-type Met cells, even
though the Db cells demonstrated a low migration
capacity and have a low metastasis rate in mammary fat
pad assays. The tail vein assays test the ability of the cells
to survive the circulatory system, to attach to a particular
site, to proliferate, and in some circumstances, to invade.
The assays do not test the ability of the cell to invade and
enter the circulation system from a distant site (as in the
mammary fat pad or subcutaneous implantation). This
assay therefore needs to be viewed with caution in
assessing the ability of cells to metastasize.
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Extracellular OPN and intracellular OPN were found by
immunohistochemistry. The extracellular OPN was
observed in the tumor necroses in both tumor lines, and
may be derived from former tumor cells or from the serum.
OPN is known to bind to components of the extracellular
matrix. The intracellular localization in the Met tumor cells
was diffusely cytoplasmic. In the normal lactating mammary
gland, OPN is predominantly found in the lumen of ducts
and alveoli. Western blotting with OPN antibody on cell
extracts and concentrated media (10-fold and 100-fold
concentrated) shows that OPN levels in the cell extracts
are similar to the levels in our previous blots, and that
OPN levels in the concentrated media fractions are
undetectable (data not shown).
These data support our immunohistochemistry observations
that OPN may be mislocalized and preferentially
sequestered in the cytoplasm. We suggest that the
potential mislocalization of OPN and potential reduction in
secreted OPN in these cells may lead to protein complexes,
which alter signaling pathways and increase the migratory
behavior of the cells. It has been demonstrated that OPN
induces increased urokinase production [48], leading to the
induction of a number of proteases (pro-MMP-1, pro-MMP-
2, pro-MMP-3, pro-MMP-9, pro-MMP-14) [49,50] that can
digest various components of the extracellular matrix as well
as being able to activate several growth factors (e.g. scatter
factor/hepatocyte growth factor, transforming growth factor
beta, basic fibroblast growth factor) that may be involved in
cell migration and invasion. In addition, SEM of these cells
suggests that OPN has an impact on the reorganization and
the remodeling of the cytoskeleton. Likewise, Zohar and
colleagues have shown that OPN may bind with an
ezrin–radixin–moesin complex (band 4.1 proteins) in
cooperation with CD44, in order to stimulate cytoskeleton
remodeling, signaling, and migration [51].
Our studies suggest that, in the PyV-mT model, an active
PI3-K pathway is associated with or induces OPN expres-
sion. These observations are not just specific to the
transplanted tumor lines analyzed in this study. Maglione
and colleagues [52] have shown OPN protein expression
in nontransplanted mammary tumors derived from PyV-mT
transgenic mice, and we have shown that nontransplanted
mammary tumors derived from Db transgenic mice do not
stain positive for OPN protein (unpublished results). This
suggests that the recruitment of PI3-K by PyV-mT has a
direct effect on OPN expression.
Zhang and colleagues [53] recently showed that the
PI3-K/Akt axis activates OPN, which increases cell motility
and anchorage independence. In addition, Kansra and
colleagues [54] showed that PI3-K is essential for the
activation of the mitogen-activated protein kinase (MAPK)
cascade (ERK and p38). Interestingly, it has been
demonstrated that p44/42 ERK/MAPK and p38 MAPK
activity increases OPN expression. Specifically, p38 and
ERK directly increase OPN transcription [55,56]. There-
fore, in our Met model, due to the activation of PI3-K, OPN
gene expression may be directly activated via PI3-K, or it
may be activated further downstream or via cross-talk
through the MAPK pathway. The direct binding of OPN to
CD44v3, the integrin pathway, or other downstream
pathways may then lead to the metastatic cascade.
The observation that the reconstitution of OPN activity in
the Db cells does not restore the metastatic phenotype
suggests that OPN itself is not sufficient for metastasis
and that other PyV-mT-triggered genes or pathways are
necessary. Hutchinson and colleagues [7] demonstrated
that restoration of Akt activity in Db mice induces rapid
tumor formation, but does not reinstate the metastatic
capacity seen in the PyV-mT model with the activated
PI3-K/Akt axis. We interpret these results, as well as our
results, to indicate that additional PI3-K-related genes are
required to functionally interact with OPN to produce the
fully metastatic phenotype. The restoration of OPN alone
in the Db cells is therefore insufficient to mediate meta-
stasis because one or more cooperating PI3-K-associated
components are absent. However, in the Met-As cells,
where the PI3-K binding component of PyV-mT is not
altered, the loss of metastatic ability can be directly
attributed to the suppression of OPN expression. The
requirement of these cooperating molecules in addition to
OPN may help explain the recent data by Wang-
Rodriguez and colleagues [57], which demonstrate that
there was not a strong correlation between OPN-positive
breast cancer and metastatic disease.
Conclusion
From our studies, it is apparent that OPN plays an
important role in the metastasis of PyV-mT mammary
tumors. The results of these experiments demonstrate that
OPN is essential for the metastatic phenotype in PyV-mT,
but that it alone is not sufficient to produce the metastatic
phenotype. This hypothesis suggests that, in OPN-positive
tumors, therapy targeting OPN may be feasible for
inhibiting the metastasis of breast cancer—either by acting
at the receptor level to block OPN binding, or by inhibiting
the activity of the PI3-K pathway or the MAPK pathway.
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